{
    "root": "3493a02e-c314-3f04-e063-6394a90a2621",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin Calcium",
    "value": "20250507",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q"
        }
    ],
    "indications": "Rosuvastatin tablets are indicated:\n                  \n                     To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor.\n                     As an adjunct to diet to:\n                     Reduce LDL-C in adults with primary hyperlipidemia.\n                     Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults.\n                     Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n                     Primary dysbetalipoproteinemia.\n                     Hypertriglyceridemia.",
    "contraindications": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH : Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH : Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 , 5.1 , 8.6 ) See full prescribing information for rosuvastatin tablets dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions": "Rosuvastatin Tablets, USP are supplied as:\n                  \n                     \n                        \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 How Supplied\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                           \n                        \n                        \n                           \n                              5 mg\n                           \n                           \n                              Bottles of 90 with child-resistant closure\n                           \n                           \n                              68071-3844-9\n                           \n                           \n                              Pink colored, film-coated, circular tablets debossed with “G” on one side and “C” on the other side.\n                           \n                        \n                        \n                           \n                              \n                           \n                           \n                           \n                           \n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions": "Rosuvastatin tablets are contraindicated in the following conditions:\n                  \n                     \n                        Acute liver failure or decompensated cirrhosis\n  \n    [see Warnings and Precautions (\n                           \n                              5.3)].\n  \n    \n                        \n                     \n                     \n                        Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets\n  \n    [see Adverse Reactions (\n                           \n                              6.1)]\n  \n    ."
}